O Brien Greene & Co. Inc Raises Holdings in Johnson & Johnson (NYSE:JNJ)

O Brien Greene & Co. Inc increased its position in Johnson & Johnson (NYSE:JNJ) by 2.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 35,208 shares of the company’s stock after buying an additional 726 shares during the quarter. Johnson & Johnson comprises about 2.3% of O Brien Greene & Co. Inc’s investment portfolio, making the stock its 16th biggest position. O Brien Greene & Co. Inc’s holdings in Johnson & Johnson were worth $5,787,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. Bluesphere Advisors LLC increased its position in shares of Johnson & Johnson by 2.3% during the first quarter. Bluesphere Advisors LLC now owns 2,593 shares of the company’s stock worth $426,000 after acquiring an additional 59 shares in the last quarter. REDW Wealth LLC increased its position in shares of Johnson & Johnson by 1.8% during the first quarter. REDW Wealth LLC now owns 3,442 shares of the company’s stock worth $566,000 after acquiring an additional 60 shares in the last quarter. Financial Advisors Network Inc. increased its position in shares of Johnson & Johnson by 2.4% during the fourth quarter. Financial Advisors Network Inc. now owns 2,686 shares of the company’s stock worth $423,000 after acquiring an additional 62 shares in the last quarter. Mather Group LLC. increased its position in shares of Johnson & Johnson by 0.6% during the fourth quarter. Mather Group LLC. now owns 10,235 shares of the company’s stock worth $1,611,000 after acquiring an additional 62 shares in the last quarter. Finally, Cordasco Financial Network boosted its holdings in Johnson & Johnson by 0.9% during the first quarter. Cordasco Financial Network now owns 7,335 shares of the company’s stock worth $1,205,000 after purchasing an additional 62 shares during the last quarter. 66.74% of the stock is currently owned by institutional investors and hedge funds.

NYSE:JNJ traded down $2.19 during mid-day trading on Friday, reaching $164.89. 167,423 shares of the company’s stock were exchanged, compared to its average volume of 7,804,719. Johnson & Johnson has a one year low of $133.65 and a one year high of $173.65. The stock has a market capitalization of $434.22 billion, a price-to-earnings ratio of 29.52, a PEG ratio of 2.65 and a beta of 0.71. The business’s fifty day moving average is $166.04. The company has a quick ratio of 1.04, a current ratio of 1.28 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Monday, April 19th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.34 by $0.25. Johnson & Johnson had a net margin of 17.95% and a return on equity of 34.62%. The business had revenue of $22.30 billion for the quarter, compared to analyst estimates of $22 billion. During the same period last year, the firm earned $2.30 earnings per share. Johnson & Johnson’s revenue for the quarter was up 7.8% compared to the same quarter last year. As a group, analysts expect that Johnson & Johnson will post 9.51 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 8th. Shareholders of record on Tuesday, May 25th were issued a $1.06 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.01. This represents a $4.24 annualized dividend and a yield of 2.57%. The ex-dividend date of this dividend was Monday, May 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 52.80%.

Several research analysts recently commented on JNJ shares. Credit Suisse Group set a $193.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Monday. Morgan Stanley began coverage on shares of Johnson & Johnson in a research note on Friday, May 28th. They issued an “overweight” rating and a $187.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $182.45.

Johnson & Johnson Profile

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also: Why is a lock-up period needed for an IPO?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.